Blood Volume in Pregnancy

Initiate bimanual uterine massage; administer Oxytocin 5 IU slow IV bolus followed by an infusion of 40 IU in 500 mL of normal saline; prepare secondary uterotonics (e.g., ergometrine or carboprost) if atony persists.

Uterine atony is the primary driver in 75% of PPH cases. Because the measured blood loss of 850 mL exceeds the 500 mL threshold for vaginal deliveries, the patient is classified as having active PPH. Immediate mechanical and pharmacological interventions are required to contract the myometrium and compress the spiral arteries, preventing further volume depletion.

Mobilize the multidisciplinary emergency team; administer 1g of intravenous Tranexamic Acid (TXA) immediately; initiate rapid infusion of balanced blood products (1:1:1 ratio of pRBC, FFP, and platelets).

A blood loss of 1600 mL post-Caesarean constitutes a massive hemorrhage. The patient's Shock Index is 1.33 (120 / 90), which is significantly above the safety threshold of 0.9, indicating severe cardiovascular compromise. Immediate activation of the MTP is required to restore volume and clotting factors, while TXA is administered to arrest hyperfibrinolysis.

Establish second large-bore IV access; ensure type and cross-match for 2 units of pRBCs are active; administer prophylactic antibiotics prior to manual exploration.

Retained placental tissue prevents the uterus from contracting uniformly, leading to persistent bleeding. Since the placenta has not delivered within the standard 30-minute window and blood loss has crossed the 500 mL PPH threshold, manual removal under regional or general anesthesia is indicated to clear the uterine cavity and halt the hemorrhage.

Administer 10 units of cryoprecipitate or 3g of fibrinogen concentrate to target a fibrinogen level >2.0 g/L; continue balanced transfusion support.

A fibrinogen level below 2.0 g/L in the context of obstetric hemorrhage is a powerful predictor of severe, uncontrolled bleeding. The patient has entered consumptive coagulopathy (DIC) triggered by the abruption. Standard crystalloid or red cell transfusion alone will worsen dilutional coagulopathy; immediate targeted replacement of fibrinogen via cryoprecipitate is critical to restore hemostasis.

Placenta Accreta Spectrum (PAS)

Placenta accreta, increta, and percreta represent abnormally invasive placentation into the myometrium, presenting a catastrophic risk of hemorrhage during delivery. The rising incidence of PAS correlates directly with increasing Caesarean delivery rates. Managing these cases requires extensive preoperative planning, including scheduling delivery at a specialized tertiary care center between 34 and 36 weeks. The operational team must include maternal-fetal medicine specialists, pelvic surgeons, interventional radiologists, and a fully prepared blood bank capable of supporting massive transfusion and cell salvage.

Blood Product Refusal Protocols (e.g., Jehovah's Witness)

Patients who decline blood products due to religious or personal beliefs require a highly structured, proactive clinical management plan. Pre-delivery optimization of hemoglobin levels, iron stores, and coagulation profiles is essential to maximize physiological tolerance to blood loss. Intraoperatively, the clinical team should utilize cell salvage systems, acute normovolemic hemodilution, and advanced non-blood hemostatic agents (such as recombinant factor VIIa or fibrinogen concentrates) where acceptable under the patient's documented advanced directive.

Acute Uterine Inversion

Uterine inversion is a rare, high-urgency emergency where the uterine fundus collapses through the cervix, often triggered by excessive cord traction. This condition causes sudden, severe hemorrhage and profound neurogenic shock that is frequently disproportionate to the visible blood loss. Immediate manual replacement (the Johnson maneuver) must be attempted before the cervical ring contracts. If manual replacement is delayed, immediate administration of uterine relaxants (tocolytics like nitroglycerin or terbutaline) is required to facilitate repositioning before starting uterotonic therapy.

Resource-Constrained or Out-of-Network Environments

In settings where standard blood bank infrastructure or cold-chain storage for oxytocin is unavailable, clinical protocols must adapt to protect patients. Sublingual misoprostol (600 mcg) serves as a vital, heat-stable alternative for preventing and treating uterine atony. Additionally, the utilization of non-pneumatic anti-shock garments (NASG) can stabilize hemodynamics and buy critical time during patient transport to a higher-level facility, illustrating how low-cost, low-tech solutions can mitigate mortality risks.